In our study, we found that a majority of patients were administered with the evidence-based drug regimen (aspirin, beta-blockers, statins and ACE inhibitors or angiotensin receptor blockers [ARB]) as recommended by guidelines for the treatment of patients with established CAD [37]. The gene discussed is ACE; the disease is coronary artery disorder.